Secondary Source New England Journal of Medicine Source Reference: Vora NL "Cell-free DNA screening and maternal cancer" N Engl J Med 2024; DOI: 10.1056/NEJMe2412259.

Download this article to explore how scientists engaged in early cancer diagnostics research can maximize methylation sequencing workflows using cutting edge methylation detection and custom capture ...

Liquid biopsy, specifically circulating cell-free DNA (cfDNA), has emerged as a powerful tool for cancer early diagnosis, prognosis, and treatment monitoring over a wide range of cancer types.

Liquid biopsies are tests that detect signs of cancer through a simple blood draw. Unlike traditional biopsies, which require removing a piece of tissue, a liquid biopsy typically looks for mutations ...

SCLC generates particularly high levels of cfDNA, likely owing to the highly metastatic nature of this cancer type. Dr. MacPherson explained that cell-free, circulating tumor DNA (ctDNA) is now ...

Liquid biopsy techniques using cell-free DNA (cfDNA) play an increasingly important role in the characterization and surveillance of solid tumors. For blood cancers, molecular response assessment ...

Conventional Cell-Based versus Cell-Free Gene Synthesis. Conventional cell-based gene synthesis requires a more complicated, time- and resource-intensive workflow to assemble, sequence, amplify, and ...

More information: Mohamed Adil et al, Preeclampsia risk prediction from prenatal cell-free DNA screening, Nature Medicine (2025). DOI: 10.1038/s41591-025-03509-w ...

Aldevron’s Alchemy™ is an exclusive cell-free DNA technology which cuts research grade linear DNA manufacturing time by over 50 percent, accelerating mRNA development projects with cleaner ...